Skip to Content

Join the 'Simeprevir' group to help and get support from people like you.

Simeprevir News

Could a Monetary Perk Help Keep HIV Patients on Their Meds?

Posted 5 days ago by Drugs.com

WEDNESDAY, June 21, 2017 – There are mixed results from a new study on the use of monetary rewards to help boost the odds that HIV-infected patients will enter care, and take their meds as directed. The study, conducted at HIV clinics in New York City and Washington, D.C., found that financial incentives such as gift cards could improve the likelihood that HIV patients would take antiretroviral medications that suppress the AIDS-causing virus. But the effect was modest in patients already receiving care, and the gift cards had little effect on increasing the number of new HIV-positive patients who got treated, the study authors said. Still, lead author Dr. Wafaa El-Sadr called the results "encouraging" and said they "should motivate efforts to pursue the further assessment of using financial incentives in HIV treatment programs and to determine their potential impact when scaled up." ... Read more

Related support groups: Harvoni, HIV Infection, Atripla, Pre-Exposure Prophylaxis, Incivek, Truvada, Epclusa, Stribild, Triumeq, Complera, Zepatier, Baraclude, Genvoya, Victrelis, Viread, Viekira Pak, Kaletra, Entecavir, Tenofovir, Norvir

Americans With HIV Staying on Lifesaving Meds Longer

Posted 31 May 2017 by Drugs.com

WEDNESDAY, May 31, 2017 – More Americans with HIV are sticking with medications that turn a fatal disease into a manageable condition, a new study shows. "This represents a lot of people who are not dying and not infecting others," said study corresponding author Ira Wilson, chair of Brown University's Health Services Policy and Practice Department, in Providence, R.I. "These differences represent tremendous, very real benefit," he added in a university news release. While there have been significant increases in how long HIV patients take their medications, many people still stop taking the drugs after a few years, the researchers cautioned. In the study, the researchers analyzed data from nearly 43,600 Medicaid patients in 14 states from 2001 to 2010, and found the length of time patients kept taking antiretroviral medications increased more than 50 percent. In 2001-2003, half of ... Read more

Related support groups: Harvoni, HIV Infection, Atripla, Pre-Exposure Prophylaxis, Incivek, Truvada, Epclusa, Stribild, Triumeq, Complera, Zepatier, Genvoya, Baraclude, Victrelis, Viread, Viekira Pak, Kaletra, Tenofovir, Norvir, Entecavir

Charlie Sheen's 2015 HIV Disclosure Spiked Use of Home Test Kits

Posted 18 May 2017 by Drugs.com

THURSDAY, May 18, 2017 – Soon after actor Charlie Sheen revealed his HIV-positive status back in late 2015, rates of at-home testing for the virus shot up to record levels, a new report shows. The study follows on 2016 research that found the the Internet was abuzz with millions more searches for HIV-related topics after the former "Two and a Half Men" star made the disclosure in November of 2015. In total, all English-language searches about HIV quadrupled beyond the usual number the day after Sheen's announcement, said a team from San Diego State University. Searches for information about HIV symptoms and testing were about six times higher than normal. And their follow-up research has now found that weekly sales of the HIV home-test kit OraQuick nearly doubled in the week after the announcement. "Charlie Sheen's disclosure is potentially the most significant domestic HIV prevention ... Read more

Related support groups: HIV Infection, Valtrex, Acyclovir, Valacyclovir, Ribavirin, Pre-Exposure Prophylaxis, Incivek, Zovirax, Baraclude, Famciclovir, Victrelis, Famvir, Viread, Daklinza, Kaletra, Norvir, Copegus, Entecavir, Ribasphere, Diagnosis and Investigation

Is the AIDS Epidemic Winding Down in the U.S.?

Posted 17 May 2017 by Drugs.com

WEDNESDAY, May 17, 2017 – Could the United States be turning the corner on the AIDS epidemic? New research suggests it's possible. If certain targets are met, the rate of new infections may be down to 12,000 a year by 2025, which would mark a transition toward the end of the HIV/AIDS epidemic, the researchers said. "Achieving these targets will require a sustained and intensified national commitment to ending the epidemic," said study author Dr. Robert Bonacci, from Brigham and Women's Hospital in Boston. "But if the U.S. does achieve a reduction to 12,000 new HIV infections by 2025, it could mark an important turning point in the U.S. HIV epidemic: a decline in the total number of people living with HIV in the U.S., and the beginning of the end of the U.S. AIDS epidemic," he said in a hospital news release. It's crucial that the goals of the U.S. National HIV/AIDS Strategy (NHAS) are ... Read more

Related support groups: HIV Infection, Pre-Exposure Prophylaxis, Incivek, Baraclude, Victrelis, Viread, Kaletra, Entecavir, Tenofovir, Norvir, Lamivudine, Telaprevir, Nevirapine, Prezista, Boceprevir, Reyataz, Abacavir, Zidovudine, Ritonavir, Tivicay

Life Expectancy With HIV Nears Normal With Treatment

Posted 11 May 2017 by Drugs.com

WEDNESDAY, May 10, 2017 – Young adults with HIV who get treatment are living longer in North America and Europe, a new study finds. In fact, a 20-year-old with HIV who began antiretroviral treatment in 2008 or later and had a low viral load after a year of treatment has a life expectancy that's close to that of the general population – around 78 years old, the study found. But life expectancy for people with HIV mostly remains lower than that of the general population, according to the study published in The Lancet HIV. The researchers said their findings could help reduce stigmatization of people with HIV and help them get jobs and medical insurance. The study should also encourage newly diagnosed HIV patients to begin treatment as soon as possible and stick with it. "Our research illustrates a success story of how improved HIV treatments coupled with screening, prevention and ... Read more

Related support groups: HIV Infection, Valtrex, Acyclovir, Tamiflu, Valacyclovir, Ribavirin, Pre-Exposure Prophylaxis, Incivek, Zovirax, Baraclude, Famciclovir, Victrelis, Famvir, Oseltamivir, Viread, Kaletra, Norvir, Ribasphere, Copegus, Ganciclovir

Black Americans Still Undertreated for HIV

Posted 3 Feb 2017 by Drugs.com

FRIDAY, Feb. 3, 2017 – Although progress has been made, blacks in America are still being hit harder by HIV/AIDS, a new report from the U.S. Centers for Disease Control and Prevention says. The CDC study found that of more than 12,200 black men and women diagnosed with HIV in 2014, nearly 22 percent had progressed to AIDS by the time they were diagnosed. That means diagnosis and treatment is often coming too late. Moreover, among all black Americans with HIV in 2013, only about 54 percent were receiving continuous medical care. Of those getting care, less than half had effectively suppressed the virus. This is far below the National HIV/AIDS Strategy goals of 90 percent of HIV patients in treatment and 80 percent with undetectable HIV by 2020, the study authors noted. "While we have made great progress in HIV prevention among African Americans in recent years, it is clear that we need ... Read more

Related support groups: HIV Infection, Valtrex, Acyclovir, Tamiflu, Valacyclovir, Ribavirin, Pre-Exposure Prophylaxis, Incivek, Zovirax, Truvada, Baraclude, Famciclovir, Victrelis, Famvir, Oseltamivir, Viread, Kaletra, Valcyte, Entecavir, Copegus

Diabetes Risk May Be Higher for HIV-Positive Adults

Posted 31 Jan 2017 by Drugs.com

TUESDAY, Jan. 31, 2017 – People infected with the virus that causes AIDS may be more likely to develop diabetes, new research suggests. In the study, the prevalence of diabetes was almost 4 percent higher among HIV-positive adults than the general population. Researchers examined survey responses of 8,610 HIV-positive participants in the Medical Monitoring Project (MMP). They also analyzed data from about 5,600 people in the general public who took the annual National Health and Nutrition Examination Survey (NHANES). Of the MMP participants, 75 percent were men and nearly 60 percent were aged 45 or older. About 25 percent were obese; about 20 percent also had hepatitis C (HCV); and 90 percent had received antiretroviral therapy within the past year. Of NHANES participants, about half were men aged 45 years and older; 36 percent were obese; and fewer than 2 percent had hepatitis C. The ... Read more

Related support groups: Obesity, Diabetes, Type 2, Metformin, Insulin, Lantus, HIV Infection, Glucophage, Glipizide, Novolog, Humalog, Glyburide, Lantus Solostar, Levemir, Pre-Exposure Prophylaxis, Glimepiride, Incivek, Novolin R, Amaryl, Novolin N, Humulin N

Newer Hepatitis C Drugs May Pose Health Risks: Study

Posted 25 Jan 2017 by Drugs.com

Newer drugs to cure hepatitis C may put patients at risk for liver failure and other severe side effects, according to a new study from a U.S. nonprofit group that examines drug safety. The study by the Institute for Safe Medication Practices is based on an analysis of U.S. Food and Drug Administration data and reports from doctors worldwide on adverse events possibly caused by the nine widely used antiviral drugs, The New York Times reported. Two of the drugs, Sovaldi and Harvoni, are so-called blockbusters made by Gilead Sciences and priced at $1,000 a pill. Sovaldi was approved in 2013 and Harvoni in 2014. These and other antiviral drugs can cure hepatitis C in 12 weeks in many patients. The number of adverse events is fairly small and the findings are not conclusive, but experts say the study published online Wednesday should serve as a warning, The Times reported. The study said ... Read more

Related support groups: Hepatitis C, Harvoni, Sovaldi, Ribavirin, Incivek, Epclusa, Victrelis, Sofosbuvir, Liver and Pancreatic Disease, Copegus, Ribasphere, Telaprevir, Rebetol, Ledipasvir/sofosbuvir, Boceprevir, Interferon Alfa-2B/Ribavirin, RibaPak, Olysio, Rebetron, Virazole

Can HIV Drugs Boost Syphilis Risk?

Posted 17 Jan 2017 by Drugs.com

MONDAY, Jan. 16, 2017 – Gay and bisexual men taking antiretroviral drugs to treat HIV infection may be at increased risk for syphilis, new research contends. Based on a review of available evidence, the investigators concluded that the drugs may boost susceptibility to the bacterium that causes syphilis, although the study did not prove cause-and-effect. The finding might explain why new and repeat cases of syphilis in gay and bisexual men have risen sharply compared to other sexually transmitted infections over the past decade, the researchers wrote. The study team was led by Dr. Michael Rekart, from the University of British Columbia's School of Population and Public Health in Vancouver. The findings were published in the Jan. 16 issue of the journal Sexually Transmitted Infections. The authors of an editorial that accompanied the study said the theory is "intriguing" and "warrants ... Read more

Related support groups: HIV Infection, Sexually Transmitted Diseases, Valtrex, Acyclovir, Tamiflu, Valacyclovir, Ribavirin, Pre-Exposure Prophylaxis, Incivek, Zovirax, Syphilis, Baraclude, Famciclovir, Victrelis, Famvir, Oseltamivir, Viread, Kaletra, Daklinza, Entecavir

Doctors Seeing More HIV Patients With Multidrug Resistance

Posted 1 Dec 2016 by Drugs.com

THURSDAY, Dec. 1, 2016 – A significant number of people with HIV have strains of the AIDS-causing virus that are resistant to both older and newer drugs, researchers report. The researchers looked at 712 HIV patients worldwide whose infection was not controlled by antiretroviral drugs. They found that 16 percent of patients whose infection was resistant to modern drugs had HIV mutations linked with resistance to older drugs called thymidine analogues. Among patients whose HIV had this mutation, 80 percent were also resistant to tenofovir, the main drug in most modern HIV treatment and prevention programs, the researchers reported. The findings were published in the Nov. 30 issue of The Lancet Infectious Diseases journal. "We were very surprised to see that so many people were resistant to both drugs, as we didn't think this was possible," study lead author Ravi Gupta, of University ... Read more

Related support groups: Harvoni, HIV Infection, Atripla, Sovaldi, Pre-Exposure Prophylaxis, Incivek, Truvada, Epclusa, Stribild, Triumeq, Complera, Zepatier, Baraclude, Genvoya, Victrelis, Sofosbuvir, Viread, Kaletra, Viekira Pak, Norvir

Antibodies May Hold Key to HIV Suppression

Posted 10 Nov 2016 by Drugs.com

WEDNESDAY, Nov. 9, 2016 – Antibodies may keep the HIV virus in check and one day let patients stop taking antiretroviral drugs, two new preliminary trials suggest. Researchers tried to quell HIV in 23 patients with infusions of an anti-HIV antibody known as VRC01. The antibody was safe and repressed blood levels of HIV for a short time before the virus reappeared, the researchers said. HIV is the virus that can lead to AIDS. "We were not expecting that we were going to see a prolonged repression, because it was only a single antibody," said co-study author Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases. The next phase is to infuse two or three antibodies intermittently, and see if antiretroviral drugs can be withdrawn permanently, he explained. After regular intravenous infusions of VRC01, participants in the U.S. National Institutes of ... Read more

Related support groups: HIV Infection, Valtrex, Acyclovir, Valacyclovir, Ribavirin, Pre-Exposure Prophylaxis, Incivek, Zovirax, Baraclude, Famciclovir, Victrelis, Famvir, Viread, Kaletra, Norvir, Ganciclovir, Copegus, Tenofovir, Ribasphere, Valcyte

HIV May Hide in Tissues, Even After Treatment

Posted 27 Oct 2016 by Drugs.com

WEDNESDAY, Oct. 26, 2016 – HIV patients who've been treated with antiretroviral drugs still have the AIDS-causing virus in their tissues, a new study suggests. Treatment with antiretrovirals eliminates detectable levels of HIV in the blood and controls the disease. But the new findings suggest that HIV in the tissues may not cause AIDS but could contribute to the development of unrelated conditions, such as cancer and heart disease, according to the University of California, San Francisco (UCSF) researchers. "Looking in tissues of treated HIV patients, we found that HIV in some tissues did not appear to be affected by antiretrovirals," said study senior author Dr. Michael McGrath. "Notably we saw no evidence of drug resistance, which we would have seen if the virus had been exposed to medications," said McGrath. He is UCSF professor of laboratory medicine at the AIDS and Cancer ... Read more

Related support groups: HIV Infection, Valtrex, Acyclovir, Sovaldi, Valacyclovir, Ribavirin, Pre-Exposure Prophylaxis, Incivek, Zovirax, Baraclude, Famciclovir, Victrelis, Sofosbuvir, Famvir, Viread, Kaletra, Ganciclovir, Copegus, Norvir, Tenofovir

Study Discounts Myth of 'Patient Zero' in U.S. AIDS Crisis

Posted 26 Oct 2016 by Drugs.com

WEDNESDAY, Oct. 26, 2016 – Using genetic analyses of 40-year-old blood samples, scientists have arrived at a clearer understanding of the introduction and spread in North America of the virus that causes AIDS. One myth already debunked by the research: That there was a "Patient Zero" who somehow caused the epidemic of human immunodeficiency virus (HIV) in the United States. "In many ways, the historical evidence has been pointing to the fallacy of Patient Zero for decades," said Dr. Richard McKay, who studies the history behind the AIDS epidemic and was a co-author on the new study. "We now have additional [genetic] evidence that helps to consolidate this position," McKay said in a news release from the University of Cambridge in England. He is a professor in the university's departments of history and philosophy of science. The new genetic research was published Oct. 26 in the journal ... Read more

Related support groups: HIV Infection, Incivek, Baraclude, Victrelis, Viread, Kaletra, Entecavir, Norvir, Diagnosis and Investigation, Tenofovir, Telaprevir, Lamivudine, Nevirapine, Boceprevir, Reyataz, Prezista, Abacavir, Epivir, Zidovudine, Ritonavir

Monkey Study Hints at Drug-Free Suppression of HIV

Posted 13 Oct 2016 by Drugs.com

THURSDAY, Oct. 13, 2016 – Scientists may have found a way to suppress an HIV-like infection in monkeys, without the need for ongoing drug therapy. The researchers added antibody therapy to standard drug treatment given to macaque monkeys infected with simian immunodeficiency virus (SIV). After three months, the animals were taken off the drugs, but their viral levels remained low to undetectable – for close to two years. Experts stressed that the animal findings need to be viewed with caution, and that many questions remain. But, they were also hopeful this could lead to a therapy that frees at least some people from their HIV drug regimens. An initial safety study has already started at the U.S. National Institute of Allergy and Infectious Diseases (NIAID). The drug "cocktails" used to treat HIV – known as combined antiretroviral therapy (ART) – have changed the face of the ... Read more

Related support groups: HIV Infection, Valtrex, Acyclovir, Valacyclovir, Ribavirin, Incivek, Zovirax, Baraclude, Famciclovir, Victrelis, Famvir, Viread, Kaletra, Ribasphere, Copegus, Diagnosis and Investigation, Ganciclovir, Valcyte, Norvir, Entecavir

FDA Medwatch Alert: Direct-Acting Antivirals for Hepatitis C: Drug Safety Communication - Risk of Hepatitis B Reactivating

Posted 10 Oct 2016 by Drugs.com

ISSUE: The FDA is warning about the risk of hepatitis B virus (HBV) becoming an active infection again in any patient who has a current or previous infection with HBV and is treated with certain direct-acting antiviral (DAA) medicines for hepatitis C virus. In a few cases, HBV reactivation in patients treated with DAA medicines resulted in serious liver problems or death. HBV reactivation usually occurred within 4-8 weeks. As a result, FDA is requiring a Boxed Warning, our most prominent warning, about the risk of HBV reactivation to be added to the drug labels of these DAAs directing health care professionals to screen and monitor for HBV in all patients receiving DAA treatment. This warning will also be included in the patient information leaflet or Medication Guides for these medicines. BACKGROUND: Direct-acting antiviral medicines are used to treat chronic hepatitis C virus (HCV) ... Read more

Related support groups: Hepatitis C, Harvoni, Hepatitis B, Sovaldi, Epclusa, Zepatier, Sofosbuvir, Daklinza, Viekira Pak, Ledipasvir/sofosbuvir, Olysio, Daclatasvir, Ombitasvir/paritaprevir/ritonavir, Simeprevir, Viekira XR, Technivie, Sofosbuvir/velpatasvir, Elbasvir/grazoprevir, Dasabuvir/ombitasvir/paritaprevir/ritonavir

Page 1 2 3 Next

Ask a Question

Further Information

Related Condition Support Groups

Hepatitis C

Related Drug Support Groups

Olysio

Simeprevir Patient Information at Drugs.com